Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
Open Access
- 1 May 2015
- journal article
- review article
- Published by Taylor & Francis Ltd in Neuropsychiatric Disease and Treatment
- Vol. ume 11, 1149-1155
- https://doi.org/10.2147/ndt.s67470
Abstract
Profile of agomelatine and its potential in the treatment of generalized anxiety disorder Michelle Nigri Levitan,1 Marcelo Papelbaum,1,2 Antonio Egidio Nardi1 1Laboratory of Panic and Respiration, Institute of Psychiatry of the Federal University of Rio de Janeiro, 2State Institute of Diabetes and Endocrinology of Rio de Janeiro, Rio de Janeiro, Brazil Background: Although many generalized anxiety disorder (GAD) patients respond to the available pharmacological treatments, nearly half of them do not present the expected results. Besides, the side effects associated to some drugs have a negative impact on treatment adherence. Therefore, the aim of this review was to report the clinical profile of agomelatine, a selective melatonergic MT1/MT2 receptor agonist with serotonin 5-HT2c receptor antagonist activities, as a potential pharmacological option in the treatment of GAD.Methods: We performed a literature review regarding studies that evaluated the use of agomelatine in GAD treatment. Results: Two short-term, double-blinded studies and one prevention-treatment trial evaluated the efficacy of agomelatine in the treatment of GAD. Agomelatine was associated with higher rates of clinical response and remission, when compared to placebo. In addition, the long-term use of agomelatine decreased the risk of relapse of anxiety symptoms, even for the severely ill patients. Besides, the tolerability was satisfactory with the absence of discontinuation symptoms, as observed in previous studies.Conclusion: The efficacy and tolerability profiles of agomelatine in the treatment of GAD were good. However, the scarce number of trials, the small sample sizes, and the use of patients without any comorbid conditions were some limitations that impaired the generalization of the results in the general population. Nevertheless, agomelatine is an attractive off-label option in the treatment of GAD that needs more conclusive evidences to establish its role in future guidelines. Keywords: agomelatine, generalized anxiety disorder, pharmacological treatmentKeywords
This publication has 36 references indexed in Scilit:
- Agomelatine in Generalized Anxiety DisorderBritish Journal of Psychology, 2014
- Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depressionHuman Psychopharmacology: Clinical and Experimental, 2013
- Clinically Significant Drug Interactions with Newer AntidepressantsCNS Drugs, 2012
- The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.CNS & Neurological Disorders - Drug Targets, 2011
- Agomelatine, the first melatonergic antidepressant: discovery, characterization and developmentNature Reviews Drug Discovery, 2010
- AgomelatineCNS Drugs, 2009
- A Double-Blind Comparison of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between Agomelatine and Venlafaxine XRJournal of Clinical Psychopharmacology, 2008
- Role of pregabalin in the treatment of generalized anxiety disorderNeuropsychiatric Disease and Treatment, 2007
- Subthreshold psychiatric disorders in primary care: prevalence and associated characteristicsJournal of Affective Disorders, 2003
- Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range studyInternational Clinical Psychopharmacology, 2002